Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Signal Genetics to introduce MyPRS Plus

Signal Genetics will introduce its next generation Multiple Myeloma Predictive Testing Product - MyPRS Plus.

MyPRS Plus offers additional insights of individual’s genetic characteristics and also identifies the molecular sub-group to which each patient belongs.

By classifying the genetic characteristics and molecular sub-group’s, one can predict the relapse and survival available for Myeloma patients.

Myeloma Health Research EVP John Shaugnessy said this classification, facilitates physicians to better understand the genetic abnormalities of their patients and use this information to make informed decisions.